Cemiplimab is a human IgG4 anti-PD-1 mAb that was approved in 2018 for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or radiation (70). The gene discussed is PDCD1; the disease is skin squamous cell carcinoma.